Another pharmacogenetic study on patients diagnosed with CML found that patients carrying the OCTN1 rs460089 allele (g.813G>C) had a significantly higher probability of achieving a stable major molecular response to imatinib than the patients expressing wild-type OCTN1 [69]. Here, SLC22A4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.